Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Dorr

Showing results (1-10 of 184) with videos related to

Pageof 19
Sort By:
Biochemical and Biophysical Research Communications|April 14, 1987
Reduced thiol content in L1210 cells treated with BSO increases DNA crosslinking by melphalanR T Dorr
Seminars in Oncology|August 1, 1990
Mitomycin, ifosfamide, and mesna in the treatment of lung cancerR T Dorr
Clinical Therapeutics|January 1, 1993
Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factorR T Dorr
Seminars in Oncology|June 1, 1988
New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin CR T Dorr
Pharmacotherapy|October 10, 1997
Pharmacology of the taxanesR T Dorr
Seminars in Oncology|February 1, 1991
Chemoprotectants for cancer chemotherapyR T Dorr
Blood Reviews|March 1, 1990
Antidotes to vesicant chemotherapy extravasationsR T Dorr
Seminars in Radiation Oncology|October 31, 1998
Radioprotectants: pharmacology and clinical applications of amifostineR T Dorr
Drugs|February 1, 1993
Interferon-alpha in malignant and viral diseases. A reviewR T Dorr
Seminars in Oncology|August 1, 1996
Cytoprotective agents for anthracyclinesR T Dorr
Pageof 19

Showing results (1-10 of 184) with videos related to

Sort By:
Pageof 19
Biochemical and Biophysical Research Communications|April 14, 1987
Reduced thiol content in L1210 cells treated with BSO increases DNA crosslinking by melphalanR T Dorr
Seminars in Oncology|August 1, 1990
Mitomycin, ifosfamide, and mesna in the treatment of lung cancerR T Dorr
Clinical Therapeutics|January 1, 1993
Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factorR T Dorr
Seminars in Oncology|June 1, 1988
New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin CR T Dorr
Pharmacotherapy|October 10, 1997
Pharmacology of the taxanesR T Dorr
Seminars in Oncology|February 1, 1991
Chemoprotectants for cancer chemotherapyR T Dorr
Blood Reviews|March 1, 1990
Antidotes to vesicant chemotherapy extravasationsR T Dorr
Seminars in Radiation Oncology|October 31, 1998
Radioprotectants: pharmacology and clinical applications of amifostineR T Dorr
Drugs|February 1, 1993
Interferon-alpha in malignant and viral diseases. A reviewR T Dorr
Seminars in Oncology|August 1, 1996
Cytoprotective agents for anthracyclinesR T Dorr
Pageof 19